Did you miss today's PreMarket Prep? Here are some of the highlights from the show.
'The Study Failed'
TheStreet's Adam Feuerstein joined this morning to analyze Neurotrope Inc (NASDAQ:NTRP)'s data results. According to the company, the Phase 2 data for their Alzheimer's drug Bryostatin showed a "positive" result that met the primary endpoint. According to Feuerstein, this is all spin.
"The study failed. That's the headline here. What they did...was to try and kind of spin something positive out of the failed study," he said. The announced results only included half the patients in the study, and the resulting P Value was "not clinically meaningful," he said.
Still, Feuerstein expects the company to move ahead with another trial, and even potentially raise money via a stock offering or a partnership with another company.
"If they're going to run larger, longer clinical trials of this Alzheimer's drug, they're going to need more money." To listen to the full interview with Feuerstein, click here
Key Technical Levels
The following stocks are some of the morning movers discussed during the show, with technical levels offered by co-hosts Joel Elconin and Dennis Dick, and Tommy Lackey, the managing partner and portfolio manager at Relativity Capital Advisors. To listen to the full interview with Lackey, click here.
Contrarian Vs. Momentum
At the end of the show, Dick and Elconin had a great discussion of the merits of contrarian trading and investing vs. momentum trading and investing.
Upcoming: On Tuesday's Show
We'll be joined by Nic Chahine, options expert and author of Create Income With Options Spreads on Marketfy.
How To Listen And Watch
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
